News Headlines

Display #
Title
Bristol-Myers Squibb’s Stock Topples as Kidney Cancer Drug Flunks Phase III Study
How Eli Lilly Allegedly Used a Fake Rule and Fake News to Protect Bad Patents
FDA Accepts Supplemental BLA and Grants Priority Review for Adcetris in Cutaneous T-Cell Lymphoma
Johnson & Johnson CEO to Stay on Trump’s Council to Go to Bat for Health Care
Researchers call for new consistent, robust standards for the development of meta-analyses
Chemists use electrochemistry to amp up drug manufacturing
FDA warns of potential contamination in multiple brands of drugs, dietary supplements
Anthem to exit Obamacare market in Virginia during 2018
Ophthotech’s Wet AMD Drug Fails to Meet Primary Endpoint in Phase III Study
Novogen Restructures, Board to Take Pay Cuts
130 Jobs Affected as Merck KGaA Relocates Accounting, Book-Keeping Team to Cut Costs
Tiny Virtual Biotech CellAct Forges $250 Million Chemo R&D Pact With Mundipharma
Merck CEO Resigns From American Manufacturing Council
FDA Removes Clinical Hold on CEL-SCI Study
New study discovers 'killer peptide' that helps eliminate resistant cancer cells
Boehringer Ingelheim achieves good growth in the first half of 2017
Researchers advise caution about recent US advice on aggressively lowering blood pressure
Egalet Cuts Workforce By 40 Percent in Expense Reduction Plan
Galapagos’ Phase II Results With GLPG1690 are ‘Extremely Exciting’
How AI robots hunt new drugs for crippling nerve disease
New CDC Report: More Americans have epilepsy than ever before
Trump declares national emergency on opioid abuse
Glucosamine supplements do not help knee or hip arthritis pain
Bleeding Money, Patrick Soon-Shiong’s NantHealth Restructures and Lays Off 300
Gilead’s HIV Triple Combo Gets Sped-up FDA Review, Decision Date Locked Down
Perrigo Unveils Sale of Two Business Units
GlaxoSmithKline Ditches Ionis Pharma’s Inotersen and IONIS-FB-LRx
FDA to expand public education campaign to focus on prevention of youth e-cigarette use
ALS IV therapy Radicava launched in U.S.
Esperion Stock Gains On Strong Phase II Data